Biolidics seeking arbitration after Japanese partner makes counterclaim in patent dispute
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
Singapore
CATALIST-LISTED medtech firm Biolidics on Thursday said it has issued a notice of arbitration (NOA) to Japan-based healthcare group Sysmex Corporation in light of disputes over intellectual property (IP).
This comes after Sysmex raised a counterclaim against Biolidics, alleging that Biolidics has breached some IP-related obligations.
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Copyright SPH Media. All rights reserved.
TRENDING NOW
Ministry of Home Affairs Permanent Secretary Pang Kin Keong to retire
Shelving S$5 billion office redevelopment plan proved ‘wise’ as geopolitical risks mount: OCBC chairman
Richard Eu on how core values, customers keep Singapore’s TCM chain Eu Yan Sang relevant
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
